Sara Al-Zubeidi
Director, Commercial Strategy Consulting Global Pricing and Market Access
Sara Al-Zubeidi is a Director with Clarivate based in London. Sara has 7+ years commercial strategy consulting experience in life sciences, specializing in global pricing and market access.
Sara leads teams for global P&MA engagements on behalf of pharmaceutical and biotechnology companies. Areas of expertise include pricing and access strategy, evidence generation for HTA submission, innovative agreement strategy, HTA landscape analysis, analogue assessments, value proposition/story development and payer objection handling/negotiation tactics. She also has extensive experience in commercial opportunity assessments, including indication and opportunity prioritization and patient flow assessments. Sara has deep expertise across a wide span of therapeutic areas with oncology, orphan/rare diseases, cardiology, renal and metabolic diseases as specialist areas of interest.
Prior to joining consulting, Sara worked in business development specifically for HEOR and Evidence Strategy teams.
Sara has a Master’s degree in Pharmacogenetics and Stratified Medicine at University College of London (UCL) and a BSc (Hons) in Medical Genetics from Queen Mary University of London.
Latest news
ShanghaiRanking’s Academic Ranking of World Universities 2026 Press Release
The 2026 Academic Ranking of World Universities (ARWU) is released today by ShanghaiRanking Consultancy. Since 2003, ARWU has been presenting the world’s top universities annually based on transparent methodology and…
Clarivate and KYBORA Partner to Help Biopharma Companies Execute Strategic Transaction Outcomes
This collaboration combines the scientific and commercial expertise of Clarivate’s Life Sciences & Healthcare Consulting practice with KYBORA’s global transaction execution capabilities to accelerate life sciences transactions London, U.K., August…
Clarivate Enhances SkyRiver to Help Libraries Share, Reuse and Create Trusted Metadata
Combining community metadata sharing, institutional choice and AI-powered record creation LONDON, UK, August 12, 2026 – Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced the…